Man Group
MYGN icon

Man Group’s Myriad Genetics MYGN Stock Holding History

Man Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.19M Buy
908,733
+630,531
+227% +$2.86M 0.01% 1119
2026
Q1 		$1.25M Buy
278,202
+196,243
+239% +$1.02M ﹤0.01% 1761
2025
Q4 		$504K Buy
+81,959
New +$594K ﹤0.01% 1891
2025
Q3 		– Sell
-37,656
Closed -$200K – 2377
2025
Q2 		$200K Buy
37,656
+911
+2% +$5.38K ﹤0.01% 2074
2025
Q1 		$326K Buy
36,745
+8,290
+29% +$99.6K ﹤0.01% 1910
2024
Q4 		$390K Buy
+28,455
New +$525K ﹤0.01% 1723
2022
Q2 		– Sell
-272,049
Closed -$5.65M – 1000
2022
Q1 		$6.86M Buy
272,049
+33,569
+14% +$859K 0.02% 762
2021
Q4 		$6.58M Buy
238,480
+105,380
+79% +$3.05M 0.02% 773
2021
Q3 		$4.3M Buy
133,100
+62,000
+87% +$2.06M 0.02% 892
2021
Q2 		$2.17M Buy
+71,100
New +$2.05M 0.01% 1203
2020
Q1 		– Sell
-80,022
Closed -$2.18M – 1783
2019
Q4 		$2.18M Sell
80,022
-170,699
-68% -$4.7M 0.01% 1307
2019
Q3 		$7.18M Buy
+250,721
New +$7.31M 0.03% 716
2018
Q4 		– Sell
-132,272
Closed -$6.08M – 2048
2018
Q3 		$6.08M Buy
132,272
+47,200
+55% +$2.1M 0.02% 882
2018
Q2 		$3.18M Buy
85,072
+2,015
+2% +$68.1K 0.01% 1164
2018
Q1 		$2.45M Buy
+83,057
New +$2.81M 0.01% 1203

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Man Group's MYGN Position: Q2 2026 in Review

Man Group increased its Myriad Genetics (MYGN) stake by 227% in Q2 2026, buying an estimated $2.86M and bringing the position to 908,733 shares worth $5.19M. The position accounts for 0.01% of the portfolio, ranked #1119.

Man Group first reported a position in MYGN in Q1 2018 and has held it in 15 quarters since. The position peaked at $7.18M in Q3 2019. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Man Group held 908,733 shares of Myriad Genetics worth $5.19M as of Q2 2026.
  • Man Group bought 630,531 Myriad Genetics shares in Q2 2026, an estimated $2.86M.
  • Myriad Genetics made up 0.01% of Man Group's portfolio in Q2 2026, its #1119 holding.
  • Man Group first reported a position in Myriad Genetics in Q1 2018 and has held it in 15 quarters since.
  • Man Group's Myriad Genetics position peaked at $7.18M in Q3 2019.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.